COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningf
Jaguar Health, Inc. issued a letter to shareholders regarding the upcoming webcast to review second-quarter earnings and clinical data from the recent phase 3 OnTarget trial of crofelemer for breast and lung cancer patients -
-
-
COMMUNIQUÉ DE PRESSE
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Dr. Elisabetsky conducts research on plant-based medicines for mental health conditions. Jaguar out-licenses botanical drug for schizophrenia treatment to Magdalena Biosciences -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
JAGX's securities remain listed and traded on Nasdaq as Jaguar announces regaining compliance with Nasdaq's bid price requirement. Updates on cancer supportive care drug crofelemer OnTarget trial results expected by July 23, 2024
